Hyperoxia elicits myocardial protection through a nuclear factor κB-dependent mechanism in the rat heart  by Tähepõld, Peeter et al.
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Objective: Hyperoxia has been previously shown to protect the heart from ischemia-
reperfusion injury. In the present study we investigated whether the cardioprotective
effects of hyperoxia were dependent on the redox-sensitive transcription factor
nuclear factor B.
Methods: Rats were kept in a hyperoxic (95% O2) environment for 60 minutes.
Their hearts were isolated immediately afterward, buffer perfused in a Langendorff
apparatus, and subjected to 25 minutes of global ischemia and 60 minutes of
reperfusion. Cardiac pressures and coronary flow were measured, and infarct size
was determined by means of triphenyl tetrazolium chloride staining. Activation of
nuclear factor B was assessed by means of the electrophoretic mobility shift assay,
whereas the inhibitor IB was evaluated by means of immunoblotting. Pharma-
cologic inhibition of nuclear factor B was achieved with 2 different agents, SN50
and pyrrolidine dithiocarbamate.
Results: Preischemic exposure to hyperoxia improved postischemic recovery of
myocardial contractile function and coronary flow and reduced infarct size. Hyper-
oxia activated pulmonary and myocardial nuclear factor B. Pretreatment with
SN50 (400 g/kg administered intraperitoneally) or pyrrolidine dithiocarbamate
(100 mg/kg administered intraperitoneally) before hyperoxia abolished the func-
tional and infarct-limiting protection. Hyperoxia reduced nuclear factor B activa-
tion in the heart during sustained ischemia and reperfusion and increased the
cytoplasmatic inhibitory factor IB. Administration of pyrrolidine dithiocarbamate
or SN50 during ischemia and reperfusion to isolated hearts from normoxic control
animals improved postischemic contractile function and coronary flow and reduced
infarct size.
Conclusions: Hyperoxia protects the rat heart against ischemia-reperfusion injury.
The cardioprotection depends on myocardial activation of the transcription factor
nuclear factor B. Our results support evidence for a dual role of nuclear factor B
in the heart.
Despite the surgical and technical improvements of cardiac surgeryover the last decades, there are still patients who require improvedmyocardial protection before surgical intervention. Recent reportssuggest the benefit of supplemental intraoperative oxygen in pa-tients undergoing major surgical procedures.1,2 However, hyper-oxia might lead to excessive generation of reactive oxygen spe-
cies and cause tissue injury.3
Reactive oxygen species are involved in the regulation of a number of cellular
processes.4 Transcription factors, such as nuclear factor B (NFB) and activator
protein 1 (AP-1), are, to a great extent, controlled by oxidative stress.5 NFB and
AP-1 are involved in the early activation of genes in response to various types of cell
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stress alone or in cooperation with each other. Under normal
physiologic conditions, NFB is held in the cytoplasm in an
inactive form by the inhibitory protein IB. During cellular
stress, IB is phosphorylated and released from the NFB
homodimer or heterodimer.5 NFB translocates to the cell
nucleus, binds to promoter-enhancer regions of the genes it
regulates, and induces their transcription. NFB regulates a
battery of genes associated with proinflammatory effects,
such as leukocyte adhesion molecules, cytokines, and che-
mokines.5,6 NFB also regulates genes that might be asso-
ciated with tissue repair and protection, such as the genes
encoding inducible nitric oxide synthase and inducible cy-
clooxygenase and the antioxidant manganese superoxide
dismutase.6,7
Recent studies have suggested that NFB plays an es-
sential role in ischemic preconditioning, an endogenous
phenomenon by which short periods of ischemia and reper-
fusion can protect the heart against a subsequent sustained
ischemic insult.8,9 Inhibition of NFB activation during
adaptation to ischemia abolished the functional protection
and infarct-limiting effect of ischemic preconditioning.8,10
However, activation of NFB in ischemia-reperfusion in-
jury without prior adaptation appears to be detrimental
because inhibition of NFB activation reduced infarct size
and improved heart function.11,12 Thus the role of NFB in
myocardial ischemia and reperfusion might be dual, with
both a cardioprotective role in ischemic preconditioning and
a detrimental role during sustained ischemia and reperfu-
sion.
We have previously shown that breathing a hyperoxic
gas (95% O2) induces systemic low-grade oxidative stress
in rats, which is evident as increased systemic conjugated
dienes, and improves heart function and reduces myocardial
necrosis after ischemia-reperfusion injury.13 The purpose of
this study was to investigate whether this preconditioning-
like response was dependent on NFB.
Materials and Methods
The investigation conforms with the “Guide for the Care and Use
of Laboratory Animals” published by the US National Institutes of
Health and was approved by the Ethics Committee for Animal
Research at the Karolinska Institutet.
Rat Heart Perfusion
Details of heart isolation and perfusion are provided elsewhere.13
Briefly, male Sprague-Dawley rats (250-300 g) were anesthetized
with midazolam (Dormicum; 1.5 mg/kg administered intramuscu-
larly) and fentanyl-fluanisone (Hypnorm; 0.1 mg/kg fentanyl and 3
mg/kg fluanisone administered intramuscularly). Heparin (200 IU)
was injected into the femoral vein, and thereafter, the hearts were
excised and the aorta was cannulated. The hearts were retrogradely
Langendorff perfused with gassed (5% CO2, 95% O2, pH 7.35-
7.45) Krebs-Henseleit buffer at 37°C at a constant pressure of 70
mm Hg. Isovolumetric recordings of left ventricular systolic pres-
sure (LVSP) and left ventricular end-diastolic pressure (LVEDP)
were obtained by using a balloon inserted into the left ventricle
through the left atrium. LVEDP was set to 5 mm Hg at the end of
the stabilization period. Coronary flow (CF) was measured by
means of timed collections of the coronary effluent. Left ventric-
ular developed pressure (LVDP) was calculated as follows:
LVDP  LVSP  LVEDP.
Heart rate (HR) was counted from the pressure curves. Global
ischemia was achieved by clamping the inflow tubing.
The experimental protocol is shown in Figure 1. Before heart
isolation and Langendorff perfusion, the rats were kept for 60
minutes in a cage, where a normoxic (atmospheric air) or hyper-
oxic (95% O2, monitoring with a gas analyzer) environment was
established. The length of hyperoxia was selected on the basis of
previous studies.13 Immediately after exposure to hyperoxia or
normoxia, the hearts were excised and buffer perfused by using the
Langendorff technique with 25 minutes of stabilization, 25 min-
utes of global ischemia, and 60 minutes of reperfusion. Only hearts
with an LVSP of 60 to 160 mm Hg, a CF of 8 to 16 mL/min, and
an HR of 240 to 360 beats/min at the end of stabilization were
included. The NFB inhibitors SN50 (400 g/kg; Calbiochem-
Novabiochem Corp) or pyrrolidine dithiocarbamate (PDTC; 100
mg/kg; Sigma Chemical Co) were injected intraperitoneally 20
minutes before 60 minutes of hyperoxia or normoxia, followed by
Langendorff perfusion (groups 3-6 in Figure 1, respectively).
Studies investigating the effects of SN50 or PDTC on hyperoxia-
induced myocardial protection were performed at a different cal-
endar time and are accompanied by separate normoxic control and
hyperoxic groups. Selection of drug concentrations and routes of
administration were based on pilot studies on functional effects
(results not shown).
Groups 7 and 8 were included to investigate whether NFB
inhibition during reperfusion influences ischemia-reperfusion in-
jury in isolated hearts. Hearts were harvested from normoxic
control animals, isolated, and buffer perfused. Starting from 3
minutes before global ischemia and throughout reperfusion, SN50
(18 mol/L final concentration)8 or PDTC (1 mmol/L)14 was
added to the perfusion buffer. During the preischemic period, the
drugs had no effect on baseline functional variables (LVEDP,
LVDP, HR, and CF).
Determination of Infarct Size
At the end of reperfusion, the hearts were perfused with 1%
triphenyl tetrazolium chloride (TTC; Sigma Chemical Co) at a
total volume of 3.0 mL delivered at 70 mm Hg. TTC stains viable
tissue red, whereas necrotic tissue remains unstained. The hearts
were fixed in 4% formaldehyde for 24 hours and thereafter pre-
served in 10% sucrose in phosphate-buffered saline. The hearts
were cut manually into 1-mm transverse slices. The sections were
visualized with a computer imaging system (LEICA Qwin; Leica
Imaging Systems), and infarct size was calculated by using Adobe
Photoshop 5.0. The infarcted area was calculated as a percentage
of total myocardial area. From each slice, an image was obtained
from both sides, and all calculations from one heart were averaged
into one value for statistics.
Tissue Sampling for Molecular Biology
Additional hearts and lungs were sampled for tissue analysis. The
hearts were freeze clamped at the end of 60 minutes of hyperoxia
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(n  7) or normoxia (n  7) for nuclear protein extraction and
electrophoretic mobility shift assay (EMSA) to evaluate whether
hyperoxia resulted in myocardial NFB activation. Hearts of 3
animals injected with SN50 before hyperoxia were analyzed to
assess the effect of SN50 on myocardial NFB activation. These
organs were freeze clamped after exposure to 0, 2, 5, 10, 20, or 60
minutes of hyperoxia (n  3 of each tissue for each time point) to
evaluate the time course of NFB activation in lungs and hearts.
Finally, the hearts were sampled for immunoblotting serially during
stabilization, ischemia, and reperfusion (n  3 from each group at
each time point) to investigate whether hyperoxia influenced NFB
activation and content of the NFB inhibitor IB.
Preparation of Nuclear Protein Extracts
Nuclear proteins were extracted from frozen heart samples, as
previously described in detail.15 Briefly, hearts were homogenized
in a microdismembrator, and lysis buffer was added. After incu-
Figure 1. Flow chart of the experimental groups included for evaluation of hemodynamic parameters and infarct
size. Rats were kept in a cage breathing 95% or greater O2 for 60 minutes (hyperoxia), or control animals were kept
in the same environment for a corresponding time period breathing atmospheric air (normoxia). Thereafter, hearts
were excised and Langendorff perfused, allowing 25 minutes of stabilization before 25 minutes of global ischemia
and 60 minutes of reperfusion. In other groups the NFB inhibitors SN50 (400 g/kg) or PDTC (100 mg/kg) were
administered intraperitoneally 20 minutes before either hyperoxia or normoxia (group 3, 4, 5, and 6, respectively)
or infused (SN50, 18 mol/L; PDTC, 1 mmol/L) during ischemia and reperfusion to hearts isolated from normoxic
control animals (groups 7 and 8).
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bation on ice, nuclei were collected by means of centrifugation for
1 minute at 8000g. The pellet was washed with 20 mmol/L KCl
buffer, centrifuged, and resuspended in 20 mmol/L KCl buffer, and
0.6 mol/L KCl was added and kept at 4°C for 30 minutes. After
centrifugation for 15 minutes at 8000g, the supernatant containing
nuclear proteins was obtained. The protein concentration was
determined by using the bicinchonic acid reagent (Pierce, Rock-
ford, Ill) with bovine serum albumin as a standard.
Figure 2. A, LVDP, LVEDP, and CF in Langendorff-perfused rat hearts subjected to 25 minutes of global ischemia and
60 minutes of reperfusion. Rats were kept in a normoxic (control) or hyperoxic (>95% O2, hyperoxia) environment
for 60 minutes before heart isolation or pretreated with the NFB inhibitor SN50 (400 g/kg administered
intraperitoneally) before exposure to hyperoxia (SN50hyperoxia) or before normoxia (SN50normoxia), followed
by Langendorff perfusion. B, Rats were subjected to either normoxia (control) or hyperoxia, and the NFB inhibitor
PDTC (100 mg/kg administered intraperitoneally) was administered before exposure to either normoxia
(PDTCnormoxia) or hyperoxia (PDTChyperoxia), followed by Langendorff perfusion, as for panel A. Data are
given as means  SEM. BI, Before global ischemia. *P < .05 versus control; #P < .05 versus hyperoxia.
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Electrophoretic Mobility Shift Assay
Nuclear extracts (16 g of protein per lane) were preincubated for
10 minutes in binding buffer (20 mmol/L Hepes [pH 7.9], 5%
glycerol, 5 mmol/L MgCl2, 0.5 mmol/L ethylenediamine tetraace-
tic acid, and 1 mmol/L dithiothreitol), followed by 30 minutes’
incubation at room temperature with 50,000 cpm of phosphorous
32–labeled probe containing the NFB binding site 5 AGT TGA
GGG GAC TTT CCC AGG C or the AP-1 binding site 5 CGC TTG
ATG AGT CAG CCC GGA A (both from Promega Biosciences,
Inc). DNA-protein complexes were electrophoresed on a 4% poly-
acrylamide gel. For supershift analysis, a rabbit polyclonal anti-p50
antibody or a rabbit polyclonal anti-c-jun antibody (both Santa Cruz
Biotechnology) were incubated with the binding buffer for 15 minutes
before adding the radiolabeled probe. For competition analysis, unla-
Figure 3. A, LVDP, LVEDP, and CF in Langendorff-perfused rat hearts subjected to 25 minutes of global ischemia and
60 minutes of reperfusion. Rats were either normoxic control animals (control) or perfused with the NFB inhibitor
SN50 (18 mol/L) during ischemia and reperfusion (SN50). B, Isolated hearts were normoxic in the absence
(control) or presence (PDTC) of PDTC (1 mmol/L) during ischemia and reperfusion. Data are given as means SEM.
*P < .05 versus control.
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beled probe in 100-fold excess was added before radiolabeled probe.
Quantification of band densities was performed with the software
Tina 2.0. Only bands on the same gel were used for calculation and
comparison.
Immunoblotting
Cytoplasmatic cardiac proteins were extracted by homogenizing
frozen tissue at a ratio of 40 mg of tissue per milliliter of lysis
buffer (1% sodium dodecylsulfate, 1 mmol/L Na vanadate, and 1
mmol/L of the protease inhibitor phenylmethylsulphonyl fluoride),
and insoluble material was removed by means of centrifugation.
Protein content was determined by using the bicinchonic acid
reagent (Pierce), with bovine serum albumin as a standard. The
lysates were mixed with 5 Laemmli buffer at a ratio of 5:1 and
boiled, and proteins were electrophoresed under reducing condi-
tions (16 g per lane), followed by transfer to presoaked nitrocel-
lulose membranes (Hybond-C pure; Amersham Life Science). The
membranes were blocked in phosphate-buffered saline/Dulbecco
medium (Gibco BRL, Life Technology) with 0.1% Tween and 5%
nonfat dry milk, followed by incubation with rabbit polyclonal
IB (Santa Cruz sc-371) diluted 1:1000. A goat anti-rabbit
(StressGen Biotechnologies) IgG-alkaline phosphatase 1:1000 di-
lution and an alkaline phosphatase conjugate substrate kit (BioRad
Laboratories) were used for visualization.
Statistical Analysis
Functional data are given as means  SEM. Differences in func-
tional recovery were tested by using 2-way analysis of variance
(ANOVA) with repeated measures on one factor, taking treatment
as an independent factor and time as a dependent factor. The
treatment-time interaction in ANOVA refers to the statistical test
of whether mean profiles for one group are the same as for the
other groups. In the case of significant interaction, simple effects
(ie, effects of one factor holding another factor fixed) were exam-
ined. Planned comparisons between the groups across factor time
were then performed. The P values were thereafter corrected
according to the Bonferroni procedure. If the sphericity assump-
tion was not met, the degrees of freedom of the F tests associated
with the time factor were reduced by multiplying each degree of
freedom by the Greenhouse-Geisser  value. Normal probability
plots were performed to confirm that the underlying model as-
sumptions were met by the data.
Infarct size is presented as box plots with median and quartiles
and with whisker plots as minimum and maximum values. Optical
densities of EMSA bands are presented either as box plots or as
scatterplots. The infarct sizes were approximately normally dis-
tributed, and thus comparisons of optical densities and infarct sizes
were performed by means of 1-way ANOVA. When significant P
values were calculated, intergroup comparisons were performed
with the Duncan post hoc test.
Results
Postischemic Contractile Function and Coronary Flow
Left ventricular developed pressure. With SN50, LVDP
decreased during reperfusion of normoxic control hearts
(group 1), and this was attenuated by hyperoxia (group 2;
P  .001; Figure 2, A). Pretreatment with SN50 (group 3)
abolished the protective effect of hyperoxia (P .003). The
differences between normoxic control hearts (group 1) and
hearts from normoxic animals pretreated with SN50 (group
4) or between normoxic control hearts (group 1) and hearts
from hyperoxic animals pretreated with SN50 (group 3)
could be due to chance (P  .2). When SN50 was added to
the perfusate during Langendorff perfusion, functional re-
covery after global ischemia was not influenced (group 7;
Figure 3, A).
Figure 4. A, Infarct size at the end of 25 minutes of global
ischemia and 60 minutes of reperfusion in hearts isolated imme-
diately after 60 minutes of normoxia (control, n  18) or 60
minutes of hyperoxia (hyperoxia, n  17) or from animals pre-
treated with the NFB inhibitor SN50 (400 g/kg administered
intraperitoneally) before either hyperoxia (SN50hyperoxia, n 
6) or normoxia (SN50normoxia, n  6) before Langendorff
perfusion or SN50 infused during ischemia and reperfusion (18
mol/L, SN50 buffer, n 7). B, Infarct size in control (control, n
18) and hyperoxic (hyperoxia, n  17) hearts or from animals
pretreated with the NFB inhibitor PDTC (100 mg/kg intraperito-
neally) before hyperoxic (PDTChyperoxia, n  13) or normoxic
(PDTCnormoxia, n  10) conditions or PDTC (1 mmol/L) infused
during ischemia and reperfusion (PDTC buffer, n  7). Data are
presented as medians and quartiles, with whiskers as minimum
and maximum values. *P < .05 versus control; #P < .05 versus
hyperoxia.
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Pretreatment with PDTC abolished the protective effect
of hyperoxia (group 5; P  .001; Figure 2, B). The
differences between normoxic control hearts and hearts
from hyperoxic animals pretreated with PDTC (group 3)
could be due to chance (P  .2). However, pretreatment
of normoxic control animals with PDTC improved postisch-
emic recovery of LVDP (P  .03; Figure 2, B).
When PDTC was added to the perfusate (group 8), post-
ischemic left ventricular function was not influenced (Fig-
ure 3, B).
Figure 5. A, EMSA of nuclear protein extracts of 6 rat hearts after 60 minutes of exposure to hyperoxia (>95% O2,
hyperoxia) incubated with a radiolabeled NFB probe. In the middle of the blot, an antibody to the p50 subunit of
NFB (p50) was added to 2 hyperoxic heart extracts, which restricted the mobility of the probe. No bands were
apparent in the extracts of 6 normoxic control hearts (control). B, EMSA of nuclear extracts of 6 rat hearts after
60 minutes of exposure to hyperoxia (hyperoxia) and 6 normoxic control hearts (control) incubated with a
radiolabeled AP-1 probe. C, Optical density of the NFB bands of 6 hyperoxic and 6 control hearts. D, Optical
density of the AP-1 bands of 6 hyperoxic and 6 control hearts. E, EMSA of nuclear protein extracts of 3 hearts from
rats pretreated with SN50 (400 g/kg administered intraperitoneally) before 60 minutes of exposure to hyperoxia
(>95% O2, SN50) and incubated with a radiolabeled NFB probe. In the next lanes competition with cold probe
(CP) or anti-p50 antibody (p50) have been used on nuclear extracts from hyperoxic hearts, and finally, nuclear
extracts from 3 hyperoxic (hyper) and 3 normoxic control hearts (con) are blotted. F, EMSA of nuclear extracts of
the same hearts as shown in panel E but incubated with a radiolabeled AP-1 probe. In the next lanes competition
with cold probe (CP) or anti-junD antibody (junD) have been used on nuclear extracts from hyperoxic hearts,
and finally, extracts from 3 hyperoxic (hyper) and 3 normoxic control hearts (con) are blotted. G, Optical density
of the NFB bands shown in panel E. H, Optical density of the AP-1 bands shown in panel F.
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Left ventricular end-diastolic pressure. With SN50,
LVEDP increased during reperfusion of normoxic control
hearts (group 1). Sixty minutes of hyperoxia immediately
before perfusion (group 2) did not significantly influence
postischemic LVEDP (Figure 2, A). The differences be-
tween normoxic control hearts (group 1) and hearts from
normoxic animals pretreated with SN50 (group 4) or be-
tween hearts from hyperoxic animals pretreated with SN50
(group 3) and normoxic control hearts could be due to
chance (P  .2). Infusion of SN50 during ischemia and
reperfusion (group 7) did not influence postischemic
LVEDP (Figure 3, A).
With PDTC, 60 minutes of hyperoxia immediately be-
fore perfusion attenuated an increase of LVEDP. Pretreat-
ment with PDTC before exposure to hyperoxia (group 5)
did not significantly influence postischemic LVEDP com-
pared with that seen in hyperoxic hearts (group 2; Figure 2,
B). The differences between hearts from normoxic animals
Figure 6. A, NFB activation serially in the lungs (upper panel) and hearts after 0, 2, 5, 10, 20, and 60 minutes of
hyperoxic exposure. Band identities were verified by means of supershift analysis with an anti-p50 antibody (p50)
added to nuclear protein extract after 10 (lungs) and 60 (hearts) minutes of hyperoxia and by means of cold-probe
competition (CP) in nuclear extracts from hearts after 60 minutes of hyperoxia. B, NFB activation during
ischemia and reperfusion in the hearts from normoxic (C) and hyperoxic (H) rats. Nuclear proteins were extracted
after 25 minutes of stabilization, 12.5 and 25 minutes of global ischemia, and 5 minutes of reperfusion before
incubation with a radiolabeled NFB probe. Competition analysis was performed by means of addition of cold
probe before adding the labeled probe (CP), and supershift analysis was performed by adding an anti-p65
antibody that caused restriction of the probe (p65). C, A representative immunoblot of cytoplasmatic proteins after
incubation with a rabbit polyclonal anti-IB antibody from the same heart samples as shown in the upper panel.
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pretreated with PDTC (group 6) and normoxic control
hearts or between hearts from hyperoxic animals pretreated
with PDTC (group 5) and normoxic control hearts could be
due to chance (P .2). PDTC added to the perfusate during
ischemia and reperfusion (group 8) reduced the increase of
LVEDP during reperfusion (P  .004; Figure 3, B).
Left ventricular systolic pressure and heart rate. The
differences in LVSP within or between the groups could be
due to chance (P  .2, data not shown). In the SN50 study
the mean HR immediately before global ischemia was
281  5 beats/min for all groups, whereas in the PDTC
study the value was 310  5 beats/min. Both preischemic
and postischemic differences within or between the groups
could be due to chance (P  .2).
Coronary flow. With SN50, CF was reduced during
reperfusion of normoxic control hearts (group 1). Pretreat-
ment with hyperoxia (group 2) inhibited this reduction (P
.001; Figure 2, A). SN50 given before exposure to hyperoxia
(group 3) abolished the beneficial effect of hyperoxia (P 
.001). The differences between normoxic control hearts and
hearts from normoxic animals pretreated with SN50 (group
4) and between normoxic control hearts and hearts from
hyperoxic animals pretreated with SN50 (group 3) could be
due to chance (P  .2; Figure 2, A). When SN50 was
administered to the isolated heart during ischemia and
reperfusion (group 7), CF was not influenced (Figure 3, A).
PDTC pretreatment (group 5) abolished the beneficial
effect of hyperoxia on CF (P  .001; Figure 2, B). The
differences between normoxic control hearts and hearts
from hyperoxic animals pretreated with PDTC or between
normoxic control hearts and hearts from normoxic control
animals pretreated with PDTC could be due to chance (P 
.2). Infusion of PDTC to the isolated heart during ischemia
and reperfusion (group 8) improved postischemic CF (P 
.05; Figure 2, B).
Infarct size
In hearts from normoxic control animals (group 1), 33% 
3% of total myocardial tissue was calculated as unstained by
TTC after 60 minutes of reperfusion. Hyperoxia (Group 2)
reduced this area to 19%  3% (P  .04; Figure 4, A).
Pretreatment with SN50 before exposure to hyperoxia
(group 3) inhibited the effect of hyperoxia (35% 7%, P
.003). The differences between normoxic control hearts and
hearts from hyperoxic animals pretreated with SN50 (group
3) or hearts from normoxic control animals pretreated with
SN50 (group 4) could be due to chance (P .2). Infarct size
was profoundly reduced when SN50 was infused during
ischemia and reperfusion (group 7, 13%  2%, P  .004).
Pretreatment with PDTC (group 5) abolished the bene-
ficial effect of hyperoxia (group 2) against necrosis (34% 
1% vs 20%  2%, P  .001; Figure 4, B). However,
pretreatment of either normoxic control or hyperoxic ani-
mals with PDTC (group 6) limited myocardial necrosis
compared with that seen in normoxic control hearts (35%
2% vs 44% 3% [P .007] and 34% 1% vs 44% 3%
[P  .004]). Administration of PDTC during ischemia and
reperfusion (group 8) also limited the necrotic area (29% 
2%, P  .001; Figure 4, B).
Activation of Transcription Factors
When hearts were sampled immediately after 60 minutes of
hyperoxia (group 2) and compared with normoxic control
hearts (group 1), activation of NFB and AP-1 was found in
nuclear extracts of all hyperoxic hearts. A representative
EMSA of nuclear extracts from 6 hyperoxic and 6 normoxic
control hearts with radiolabeled NFB probe is shown in
Figure 5, A, where the bands could be supershifted with
anti-p50 antibody. The band optical densities were in-
creased by means of hyperoxia (Figure 5, C). When the
same samples were incubated with a radiolabeled AP-1
probe, activation of AP-1 was found after 60 minutes of
hyperoxia (Figure 5, B and D). In the lungs sampled serially
after different durations of hyperoxia, NFB was activated
already after 2 minutes and thereafter gradually decreased
during 60 minutes of exposure (Figure 6, A). In the hearts
activation of NFB could be seen after 2 to 5 minutes of
exposure, was thereafter reduced, and increased again at the
end of 60 minutes of hyperoxia. The identity of the proteins
bound to the probe was verified by means of supershift
analysis and cold-probe competition (Figure 6, A).
Effect of SN50 on NFB and AP-1 Activation
EMSA of nuclear extracts from 3 normoxic control hearts
(group 1) and 3 hyperoxic hearts (group 2) after incubation
with the radiolabeled NFB probe is shown in Figure 5, E.
Incubation with anti-p50 caused restriction of the probe, and
the band could be abolished with cold-probe competition.
The NFB inhibitor SN50 administered before exposure to
hyperoxia (group 3) reduced activation of the transcription
factor. The band optical densities are shown in Figure 5, G.
The NFB inhibitor SN50 also reduced the AP-1 band
(Figure 5, F and H). When an anti-junD antibody was
included, the probe was restricted and abolished by means
of cold-probe competition.
NFB During Ischemia and Reperfusion
The myocardial NFB translocations during Langendorff
perfusion, ischemia, and reperfusion are shown in Figure 6,
B. In hearts isolated from normoxic control animals (group
1), NFB was activated after 25 minutes of Langendorff
perfusion and remained activated during ischemia and early
reperfusion. In hearts from hyperoxic animals (group 2), in
contrast, a consistently reduced activation of NFB than
seen in hearts from control animals was observed. The band
identities were verified by means of supershift and cold-
probe competition.
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IB Levels During Ischemia and Reperfusion
A representative immunoblot of cytoplasmatic proteins after
incubation with a rabbit polyclonal antibody against the
inducible inhibitory protein IB is shown in Figure 6, C.
Hyperoxia increased the bands for IB during stabiliza-
tion, ischemia, and reperfusion.
Discussion
In the present study we demonstrate that pretreatment of rats
with hyperoxia improved recovery of contractile function
and reduced the extent of myocardial necrosis in the isolated
hearts subjected to global ischemia and reperfusion. NFB
and AP-1 were activated in the hearts by means of hyper-
oxia, and inhibition of NFB activation with 2 different
pharmacologic agents abolished the beneficial effects.
Hearts from hyperoxic animals had less NFB activation
during ischemia and reperfusion. This might be due to an
increase of the inducible NFB inhibitory protein IB.
Thus we suggest that NFB plays a dual role in the heart. It
might play a key role in the myocardial adaptation to
ischemia presently induced by hyperoxia, but it also has a
detrimental role in hearts not adapted to sustained ischemic
insult. When the NFB inhibitor PDTC was infused into the
isolated heart during ischemia and reperfusion, the postisch-
emic recovery of myocardial contractile function was im-
proved, whereas PDTC and SN50 both reduced infarct size.
It has previously been demonstrated by us16 and others17
that low doses of exogenous reactive oxygen species might
protect myocardial function, indicating that moderate oxi-
dative stress is cardioprotective. Normobaric hyperoxia in-
duces oxidative stress in cell cultures.18 Li and colleagues19
have demonstrated that NFB is activated by means of
hyperoxia in cultured human alveolar epithelial cells. In the
present study we found that NFB becomes activated in a
time-dependent manner starting in the lungs and rapidly
followed by activation in the heart during hyperoxic expo-
sure. In the lungs NFB activation gradually decreased,
whereas in the heart it followed a biphasic pattern, with a
second peak after 20 to 60 minutes of hyperoxic exposure.
At the moment, we do not know how systemic hyperoxia
causes activation of cardiac NFB. To inhibit cardiac NFB
activation, we used the synthetic peptide SN50, which is a
highly specific NFB inhibitor.20 The present study showed
that beneficial functional and anti-infarct effects of hyper-
oxic exposure were completely blocked with SN50 in iso-
lated rat hearts. Results from EMSA analysis suggest that
SN50 did not completely inhibit activation of myocardial
NFB. A higher concentration of SN50 might have abol-
ished the activation. Another NFB inhibitor, PDTC, which
suppresses NFB activation through inhibiting the revers-
ible release of the inhibitory protein IB,14 reduced the
functional protection and infarct-limiting effects of hyper-
oxia. PDTC has also been shown to possess antioxidant
properties.21 Pretreatment of normoxic animals with PDTC,
but not SN50, before heart isolation attenuated the postisch-
emic depression of myocardial function, indicating that
antioxidant properties of PDTC might have been of impor-
tance.
Our present findings are in accordance with studies in-
vestigating the role for NFB in ischemic preconditioning.
Maulik and coworkers8 demonstrated that ischemic precon-
ditioning of isolated rat hearts induced translocation of
NFB, and SN50 inhibited the achieved cardioprotection.
Similarly, Morgan and associates10 inhibited precondition-
ing in rabbits by using the NFB inhibitor ProDTC. Xuan
and associates9 showed that even delayed cardioprotection
by means of preconditioning of the heart was abolished by
means of pharmacologic inhibition of NFB.
NFB and AP-1 are activated also during prolonged
ischemia and reperfusion of the heart.22,23 In studies on
sustained ischemia-reperfusion injury, NFB activation ap-
pears to play a detrimental role because its inhibition with
nonsense decoy oligos improves functional recovery and
reduces infarction.11,12 These results are supported by our
findings of a moderate reduction of infarction and improve-
ment of postischemic cardiac function when PDTC was
administered to control animals before heart isolation. Fur-
thermore, using PDTC or SN50 during perfusion of the
isolated heart improved functional recovery and reduced
myocardial necrosis after global ischemia. However, the
effects of PDTC on postischemic contractile function were
more apparent than the effects of SN50 and might have been
secondary to its antioxidant effect. Taken together, our data
support that activation of NFB in ischemia without previ-
ous adaptation is detrimental.
The beneficial effects of NFB activation by means of
hyperoxia or preconditioning could be related to anti-in-
flammatory effects caused by upregulation of the rapidly
inducible IB, thereby reducing inflammation during sus-
tained ischemia by inhibiting NFB activation. Hearts from
animals subjected to hyperoxia had less NFB activation
during Langendorff perfusion, induced global ischemia, and
reperfusion than hearts from normoxic control animals. Our
findings are in accordance with those in isolated, classic,
preconditioned rabbit hearts.10 Furthermore, the NFB in-
hibitor IB, which is transcriptionally induced by means
of NFB activation, was upregulated in hyperoxic hearts
during sustained ischemia. These findings indicate that the
benefit of NFB activation during adaptation to ischemia is
partly an anti-inflammatory effect caused by upregulation of
NFB activation. However, the beneficial effect of hyper-
oxia could be also due to transcription of an NFB-regu-
lated beneficial gene,24 but the latter is not investigated in
the present study.
In conclusion, the present study demonstrates that in vivo
exposure to short-term hyperoxia profoundly protects heart
function and preserves cell viability through an NFB-
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dependent mechanism. In this study the heart was the only
organ investigated, but it is likely that the protective effects
of hyperoxia are systemic. Theoretically, hyperoxia might
increase the endogenous defense in all cell types. Such a
concept is in agreement with recent findings, in which
hyperoxia reduces wound infections1 and augments antimi-
crobial defenses.2 We speculate that ventilation with a hy-
peroxic gas might be used in patients to protect any organ or
the whole organism, for instance in connection with possi-
ble complications accompanying major operations.
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